logo
Polkadot Joins BitBasel's 'Art for Impact' Program to Send Artwork to the Moon

Polkadot Joins BitBasel's 'Art for Impact' Program to Send Artwork to the Moon

Global call for artists: Submit work inspired by the 17 United Nations Sustainable Development Goals to be preserved on the lunar surface
Miami, FL – April 29, 2025 – Polkadot has joined BitBasel's Art for Impact Space Program, a visionary initiative inviting artists to create work inspired by the 17 United Nations Sustainable Development Goals (SDGs) for inclusion in a permanent art archive headed to the surface of the Moon.
This one-of-a-kind program is part of the GLPH (Galactic Library Preserve Humanity) archival payload, set to launch on the upcoming Astrobotic Griffin-1 lunar mission under NASA's Commercial Lunar Payload Services (CLPS) program. Using Nanofiche, a space-grade technology designed to endure the extreme conditions of space, selected artworks will be preserved for billions of years on the Moon as a testament to human creativity, purpose, and legacy.
Polkadot, one of Web3's most powerful and sustainable blockchain ecosystems, joins BitBasel in rallying creators around the world to contribute visual works that reflect on one or more of the 17 SDGs, including climate action, quality education, gender equality, clean energy, and sustainable innovation.
Submissions must be representable as still imagery and may include digital art, photography, illustration, painting, or mixed media. Artists are encouraged to create pieces that not only showcase their talent but also spark global awareness and inspire future generations.
A curation committee composed of representatives from BitBasel, Polkadot, GLPH, and the University of Florida Blockchain Lab will evaluate submissions and select the final group of artworks to be included in the Moon-bound archive. Selected artists will be formally recognized as part of this historic cultural and space mission.
'This is a once-in-a-lifetime opportunity for artists to etch their values into history—literally,' said Scott Spiegel, Co-founder & CEO of BitBasel. 'With Polkadot's support, we're expanding the reach of this mission across the Web3 ecosystem and beyond. The Moon is the canvas, and together we're sending a message that art can drive awareness, action, and legacy.'
The submission deadline is May 9, 2025, and the selected works will launch aboard a SpaceX rocket later this year.
To learn more and submit your artwork, visit form.typeform.com/to/EiS1sHtG
For media inquiries, please contact Jonathan Duran at Jonathan(at)Distractive(dot)xyz
###
About BitBasel
BitBasel is a pioneering platform at the intersection of art, blockchain, and emerging technology. Founded in Miami in 2020, BitBasel empowers artists, collectors, and technologists through immersive experiences, curated exhibitions, and digital marketplaces. With a mission to 'Pioneer the Future of the Arts,' BitBasel has launched historic initiatives—from lunar art missions to global Web3 education programs.
About Polkadot
Polkadot is the powerful, secure core of Web3, providing a shared foundation that unites some of the world's most transformative apps and blockchains. Polkadot offers advanced modular architecture that allows devs to easily design and build their own specialized blockchain projects, pooled security that ensures the same high standard for secure block production across all connected chains and apps connected to it, and robust governance that ensures a transparent system where everyone has say in shaping the blockchain ecosystem for growth and sustainability. With Polkadot, users are not just participants, they're co-creators with the power to shape its future.
About GLPH
The Galactic Library Preserve Humanity (GLPH) is a groundbreaking archival initiative using Nanofiche technology to preserve humanity's cultural legacy on the Moon for billions of years.
About University of Florida Blockchain Lab
The University of Florida Blockchain Lab is an academic research center advancing the development and application of blockchain technology through education, innovation, and interdisciplinary collaboration.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Eric Trump has a strong message for 'earliest believers'
Eric Trump has a strong message for 'earliest believers'

Yahoo

time4 hours ago

  • Yahoo

Eric Trump has a strong message for 'earliest believers'

Eric Trump has a strong message for 'earliest believers' originally appeared on TheStreet. The Trump family is involved with several crypto projects, one of them being a decentralized finance (DeFi) venture called the World Liberty Financial. While President Donald Trump himself acts as the chief crypto advocate at the project, his sons Donald Jr., Eric, and Barron act as Web3 ambassadors there. The family holds a 60% stake in the project. The crypto project has also launched USD1. It is a stablecoin, a type of cryptocurrency that, unlike usually volatile cryptocurrencies such as Bitcoin, maintains a stable value. It is usually pegged to a fiat currency like the U.S. dollar or a commodity like gold. USD1, as the name suggests, is pegged 1:1 to the dollar. It says it is 100% backed by short-term U.S. government treasuries, USD deposits, and other cash equivalents. On June 3, the on-chain analytics platform Lookonchain revealed on X that World Liberty Financial has been airdropping USD1 stablecoins to wallets that participated in the sale of WLFI, the project's native token. World Liberty Financial's ambassador Eric Trump congratulated "our earliest believers" for receiving the USD1 stablecoin. As per DeFiLlama, the total market cap of stablecoins stands at $249.26 billion at the time of writing. With Tether's USDT and Circle's USDC occupying more than 85% of the market share, the USD1 stablecoin accounts for a mere 0.0087% share. The USD1 stablecoin has become a bone of contention between the Republican and Democrat senators. The former believe the president's involvement with the USD1 project leads to conflicts of interest and have proposed multiple amendments to the GENIUS Act that deals with stablecoin regulation. Eric Trump has a strong message for 'earliest believers' first appeared on TheStreet on Jun 4, 2025 This story was originally reported by TheStreet on Jun 4, 2025, where it first appeared.

0602K + Tirzepatide Muscle Mass / Function and Adipose Transformation Data to be Presented at ADA Scientific Sessions
0602K + Tirzepatide Muscle Mass / Function and Adipose Transformation Data to be Presented at ADA Scientific Sessions

Yahoo

time10 hours ago

  • Yahoo

0602K + Tirzepatide Muscle Mass / Function and Adipose Transformation Data to be Presented at ADA Scientific Sessions

GRAND RAPIDS, Mich., June 4, 2025 /PRNewswire/ -- Cirius Therapeutics, Inc., developing innovative therapies for patients suffering from diseases caused by insulin resistance, including obesity/overweight and type 2 diabetes (T2D), today announced that new preclinical data combining lead candidate 0602K and tirzepatide as a late-breaking poster will be presented at the American Diabetes Association's (ADA) 85th Scientific Sessions, taking place June 20–23, 2025, at McCormick Place Convention Center in Chicago, Illinois. Presentation details: Title: 1982-LB - MPC-Directed Insulin Sensitizer MSDC-0602K Combines with Tirzepatide to Maintain Muscle Mass/Function and Restructure Adipose Tissue [Board No. 1982] Authors: M. Abu-Farha, J. Abubaker, F. Almulla, M. Abdul-Ghani, L. Norton, R.A. DeFronzo,J.R. Colca, K.S. McCommis Date & Time: Sunday, June 22, 2025, at 12:30 AM CT Location: Poster Hall (Hall F1) The abstract for this late-breaking poster will be available beginning Friday, June 20, 2025 at 6:30 PM CT. About CiriusCirius is a clinical-stage pharmaceutical company focusing on mitochondrial pyruvate carrier (MPC), addressing the metabolic dysfunction that causes insulin resistance and the organ pathologies associated with type 2 diabetes (T2D) and obesity/overweight. Its lead product candidate, 0602K (azemiglitazone potassium), is a potential best-in-class small molecule being developed as a once-daily oral therapy designed to selectively inhibit the mitochondrial target MPC, which plays a central role in selecting mitochondrial energy substrates. MPC inhibition reprograms mitochondrial metabolism, reducing insulin resistance in cells and driving metabolic benefits in organs throughout the body. This markedly improves glycemic control in T2D, body composition in obesity, liver function and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH), and outcomes in cardiometabolic disorders. About 0602K0602K has completed 7 US clinical trials including a 52-week placebo-controlled Phase 2b study in 392 subjects with MASH with and without T2D, and a 28-day placebo-controlled Phase 2a study in 129 subjects with T2D. In those clinical studies it markedly lowered HbA1c and insulin levels, and reduced liver injury and MASH – including on top of existing GLP-1 therapy. Preclinical studies also demonstrate increased lean muscle mass and function, together with marked metabolically beneficial shifts in adipose tissue phenotype ("bad fat" to "good fat"), including increased brown adipose tissue ("brown fat"). Selectively targeting MPC – while avoiding PPAR-γ activation – 0602K harnesses the real-world proven efficacy of 1st generation insulin sensitizers, such as pioglitazone, but without their side effect concerns. Directly correcting a major underlying pathophysiology of chronic metabolic disease, 0602K has the potential to become a cornerstone of therapy. Coupling this potent pharmacology with that of the GLP-1s could particularly benefit patients with T2D, obesity/overweight and other diseases. View original content to download multimedia: SOURCE Cirius Therapeutics

0602K + Tirzepatide Muscle Mass / Function and Adipose Transformation Data to be Presented at ADA Scientific Sessions
0602K + Tirzepatide Muscle Mass / Function and Adipose Transformation Data to be Presented at ADA Scientific Sessions

Yahoo

time15 hours ago

  • Yahoo

0602K + Tirzepatide Muscle Mass / Function and Adipose Transformation Data to be Presented at ADA Scientific Sessions

GRAND RAPIDS, Mich., June 4, 2025 /PRNewswire/ -- Cirius Therapeutics, Inc., developing innovative therapies for patients suffering from diseases caused by insulin resistance, including obesity/overweight and type 2 diabetes (T2D), today announced that new preclinical data combining lead candidate 0602K and tirzepatide as a late-breaking poster will be presented at the American Diabetes Association's (ADA) 85th Scientific Sessions, taking place June 20–23, 2025, at McCormick Place Convention Center in Chicago, Illinois. Presentation details: Title: 1982-LB - MPC-Directed Insulin Sensitizer MSDC-0602K Combines with Tirzepatide to Maintain Muscle Mass/Function and Restructure Adipose Tissue [Board No. 1982] Authors: M. Abu-Farha, J. Abubaker, F. Almulla, M. Abdul-Ghani, L. Norton, R.A. DeFronzo,J.R. Colca, K.S. McCommis Date & Time: Sunday, June 22, 2025, at 12:30 AM CT Location: Poster Hall (Hall F1) The abstract for this late-breaking poster will be available beginning Friday, June 20, 2025 at 6:30 PM CT. About CiriusCirius is a clinical-stage pharmaceutical company focusing on mitochondrial pyruvate carrier (MPC), addressing the metabolic dysfunction that causes insulin resistance and the organ pathologies associated with type 2 diabetes (T2D) and obesity/overweight. Its lead product candidate, 0602K (azemiglitazone potassium), is a potential best-in-class small molecule being developed as a once-daily oral therapy designed to selectively inhibit the mitochondrial target MPC, which plays a central role in selecting mitochondrial energy substrates. MPC inhibition reprograms mitochondrial metabolism, reducing insulin resistance in cells and driving metabolic benefits in organs throughout the body. This markedly improves glycemic control in T2D, body composition in obesity, liver function and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH), and outcomes in cardiometabolic disorders. About 0602K0602K has completed 7 US clinical trials including a 52-week placebo-controlled Phase 2b study in 392 subjects with MASH with and without T2D, and a 28-day placebo-controlled Phase 2a study in 129 subjects with T2D. In those clinical studies it markedly lowered HbA1c and insulin levels, and reduced liver injury and MASH – including on top of existing GLP-1 therapy. Preclinical studies also demonstrate increased lean muscle mass and function, together with marked metabolically beneficial shifts in adipose tissue phenotype ("bad fat" to "good fat"), including increased brown adipose tissue ("brown fat"). Selectively targeting MPC – while avoiding PPAR-γ activation – 0602K harnesses the real-world proven efficacy of 1st generation insulin sensitizers, such as pioglitazone, but without their side effect concerns. Directly correcting a major underlying pathophysiology of chronic metabolic disease, 0602K has the potential to become a cornerstone of therapy. Coupling this potent pharmacology with that of the GLP-1s could particularly benefit patients with T2D, obesity/overweight and other diseases. View original content to download multimedia: SOURCE Cirius Therapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store